Literature DB >> 16261353

Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.

Eduardo A Marques-da-Silva1, Eduardo A F Coelho, Daniel C O Gomes, Márcia C Vilela, Cássio Z Masioli, Carlos A P Tavares, Ana Paula Fernandes, Luis Carlos C Afonso, Simone A Rezende.   

Abstract

Acute visceral leishmaniasis is a progressive disease caused by Leishmania chagasi in South America. The acquisition of immunity following infection suggests that vaccination is a feasible approach to protect against this disease. Since Leishmania homologue of receptors for activated C kinase (LACK) antigen is of particular interest as a vaccine candidate because of the prominent role it plays in the pathogenesis of experimental Leishmania major infection, we evaluated the potential of a p36(LACK) DNA vaccine in protecting BALB/c mice challenged with L. chagasi. In this study, mice received intramuscular (i.m.) or subcutaneous (s.c.) doses of LACK DNA vaccine. We evaluated the production of vaccine-induced cytokines and whether this immunization was able to reduce parasite load in liver and spleen. We detected a significant production of interferon gamma by splenocytes from i.m. vaccinated mice in response to L. chagasi antigen and to rLACK protein. However, we did not observe a reduction in parasite load neither in liver nor in the spleen of vaccinated animals. The lack of protection observed may be explained by a significant production of IL-10 induced by the vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261353     DOI: 10.1007/s00436-005-0008-8

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  20 in total

1.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells.

Authors:  S Gurunathan; L Stobie; C Prussin; D L Sacks; N Glaichenhaus; A Iwasaki; D J Fowell; R M Locksley; J T Chang; C Y Wu; R A Seder
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

3.  Expression cloning of a protective Leishmania antigen.

Authors:  E Mougneau; F Altare; A E Wakil; S Zheng; T Coppola; Z E Wang; R Waldmann; R M Locksley; N Glaichenhaus
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

4.  Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK.

Authors:  Maria J Ramiro; Juan J Zárate; Tobias Hanke; Dolores Rodriguez; Juan R Rodriguez; Mariano Esteban; Javier Lucientes; Juan A Castillo; Vicente Larraga
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

5.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.

Authors:  Eduardo Antonio Ferraz Coelho; Carlos Alberto Pereira Tavares; Fernando Aécio Amorim Carvalho; Karina Figueiredo Chaves; Kadima Nayara Teixeira; Rafaela Chitarra Rodrigues; Hugues Charest; Greg Matlashewski; Ricardo Tostes Gazzinelli; Ana Paula Fernandes
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

7.  Effects of ageing on the immunoregulation of parasitic infection.

Authors:  Neil E Humphreys; Richard K Grencis
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

8.  Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis.

Authors:  L C Afonso; P Scott
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

9.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  17 in total

1.  Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice.

Authors:  Stella Costa Silva; Débora Faria Silva; Tamires Cunha Almeida; Fernanda Barçante Perasoli; André Talvani Pedrosa da Silva; Glenda Nicioli da Silva; Simone Aparecida Rezende
Journal:  Parasitol Res       Date:  2018-06-25       Impact factor: 2.289

2.  Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.

Authors:  Vahid Heravi Shargh; Mahmoud Reza Jaafari; Ali Khamesipour; Seyed Amir Jalali; Hengameh Firouzmand; Azam Abbasi; Ali Badiee
Journal:  Parasitol Res       Date:  2012-01-06       Impact factor: 2.289

Review 3.  Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2017-07-05

4.  Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis.

Authors:  Flávia M Ferreira; Renata A O Castro; Mauricio A Batista; Fernanda M O Rossi; Denise Silveira-Lemos; Frédéric Frézard; Sandra A L Moura; Simone A Rezende
Journal:  Parasitol Res       Date:  2013-11-30       Impact factor: 2.289

5.  Protective effect of lectin from Synadenium carinatum on Leishmania amazonensis infection in BALB/c mice.

Authors:  Sandra R Afonso-Cardoso; Flavio H Rodrigues; Marcio A B Gomes; Adriano G Silva; Ademir Rocha; Aparecida H B Guimaraes; Ignes Candeloro; Silvio Favoreto; Marcelo S Ferreira; Maria A de Souza
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

6.  In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response.

Authors:  Negar Seyed; Farnaz Zahedifard; Shima Safaiyan; Elham Gholami; Fatemeh Doustdari; Kayhan Azadmanesh; Maryam Mirzaei; Nasir Saeedi Eslami; Akbar Khadem Sadegh; Ali Eslami Far; Iraj Sharifi; Sima Rafati
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

7.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

Review 8.  The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates.

Authors:  Greta Volpedo; Parna Bhattacharya; Sreenivas Gannavaram; Thalia Pacheco-Fernandez; Timur Oljuskin; Ranadhir Dey; Abhay R Satoskar; Hira L Nakhasi
Journal:  Pathogens       Date:  2022-04-02

9.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007

10.  Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.

Authors:  Manuel Soto; Laura Corvo; Esther Garde; Laura Ramírez; Virginia Iniesta; Pedro Bonay; Carlos Gómez-Nieto; Víctor M González; M Elena Martín; Carlos Alonso; Eduardo A F Coelho; Aldina Barral; Manoel Barral-Netto; Salvador Iborra
Journal:  PLoS Negl Trop Dis       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.